- Company
- Boryung released Avastin Biosimilar for the first time
- by An, Kyung-Jin Sep 5, 2021 08:24pm
- Boryung announced that it will sell its anti-cancer biosimilar "Onbevezy" introduced by Samsung Bioepis in the domestic market from the 1st. Onbevezy is a biosimilar product of the blockbuster anti-cancer drug Avastin (Bevacizumab) developed by Roche. Samsung Bioepis proved the equivalent effect and safety of its original product Avastin t
- Company
- Academia supports 1st-line reimbursement of Tagrisso
- by Eo, Yun-Ho Sep 3, 2021 06:03am
- The lung cancer societies are supporting the need to extend insurance benefits for ‘Tagrisso’ to 1st line treatment in lung cancer. In July, AstraZeneca Korea had reduced the standards and reapplied to extend reimbursement to the reduced scope for its 3rd generation EGFR TKI Tagrisso (osimertinib). However, the Health Insurance Review a
- Policy
- GOV to bring 1.5 mil COVID-19 vaccines from Romania
- by Kim, Jung-Ju Sep 3, 2021 06:03am
- The Korean government has secured 1,503,000 doses of Pfizer and Modena’s COVID-19 vaccines from Romania and will bring the vaccines to Korea in two shipments this week and next week. The swap was made in line with cooperation for preventive measures against the pandemic that was discussed between the two countries from last month to exch
- Company
- Kymriah was virtually pending at the Committee
- by Eo, Yun-Ho Sep 2, 2021 05:59am
- It wasn't easy: the listing of the super expensive one-shot treatment 'Kymriah's insurance benefits was discussed but put on hold. According to related industries, Novartis Korea's world's first CAR-T treatment, Kymriah(Tisagenlecleucel), was virtually pending at the HIRA Cancer Drugs Benefit Appraisal Committee on the 1st. However, based on
- Policy
- Eligibility for adjustment applications improved
- by Lee, Hye-Kyung Sep 2, 2021 05:59am
- The criteria for adjustment applications that affect drugs subject to pricing calculations will be improved. On the 2nd, the Health Insurance Review and Assessment Service (HIRA) will present the ‘proposal to improve the assessment criteria for drugs that apply for drug pricing adjustments’ as an agenda for deliberation for its Drug Rei
- Company
- First IV acetaminophen+ibuprofen combo lands in Korea
- by An, Kyung-Jin Sep 2, 2021 05:59am
- An acetaminophen+ibuprofen solution for infusion will soon be released in the Korean pharmaceutical market. Whether the introduction of a new combination therapy option in the single drug-oriented nonopioid analgesic infusion space is gaining attention. According to industry sources on the 1st, Kyongbo Pharmaceutical had received marketi
- Company
- Sputnik V's lot release is imminent
- by Kim, Jin-Gu Sep 2, 2021 05:59am
- The Russian COVID vaccine Sputnik V is about to be released, Korus Pharm said on Tuesday. According to Korus Pharm, local administrative procedures for Sputnik V's lot release are being finalized. The production of finished products with a capacity of 1000L has already been completed, and it is expected that the product will be released in
- Company
- SK Bioscience has started clinical trial of GBP510
- by Chon, Seung-Hyun Sep 2, 2021 05:59am
- Phase 3 of COVID vaccine developed in Korea have begun in earnest. SK Bioscience announced on the 30th that it has started administering the first subjects of phase 3 clinical trials of GBP510, jointly developed by the Institute for Protein Design (IPD) at the University of Washington. This is the first phase 3 clinical trial of a candidate subs
- Company
- It is necessary to provide Kymriah treatment accessibility
- by Sep 2, 2021 05:59am
- Novartis Korea (CEO Kim Skafte Mortensen) announced on the 30th that the ICBMT released the results of a study that analyzed the treatment of DLBCL patients in Korea from August 26 at ICBMT. DLBCL is an aggressive lymphoma that accounts for about 40% of non-Hodgkin lymphoma. Although most standard treatments show abnormalities in part, it
- Company
- ‘Somavert’ is reimbursed and starts landing in GHs
- by Eo, Yun-Ho Sep 1, 2021 05:57am
- The new acromegaly drug ‘Somavert’ was listed for insurance benefit and has begun landing in general hospitals. According to industry sources, Pfizer Korea’s Somavert (pegvisomant) has submitted landing applications to drug committees at major medical institutions including the Seoul National University Hospital, Severance Hospital, a
